INS and metabolic dysfunction-associated steatotic liver disease: On the contrary, patients on insulin therapy for diabetes had a higher prevalence of NAFLD (40% in the NAFLD group vs. 25% in the non-NAFLD group) (p ≤ 0.001) (Table 2).